What is the efficacy of Haemophilus influenzae type b (Hib) conjugate vaccine in the prevention of Haemophilus influenzae infections?

Updated: Jun 11, 2021
  • Author: Joseph Adrian L Buensalido, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD  more...
  • Print

In the primary series, administer a 3-dose regimen of HbOC or PRP-T or a 2-dose regimen of PRP-OMP at 2-months intervals, beginning at age 2 months. Any conjugate Hib vaccine can serve as the booster immunization given in children aged 12-15 months. Lack of the booster dose in the United Kingdom might be a reason for the recent increase in Hib disease since the Hib vaccine was introduced there in 1992.

A 2017 stochastic modelling of Hib transmission dynamics aimed to compare the long-term effects of booster vaccination and various booster timings after receipt of the primary series and the subsequent incidence of disease and asymptomatic carriage. The results showed that the incidence of asymptomatic carriage for an average 2-year delay in the booster was comparable or even lower than if the booster was given within 1 year of the primary series. The results were similar for symptomatic disease. The findings highlight the importance of booster vaccination so that the incidence of Hib infections will continue to decrease. [108]

Children with decreased or absent splenic function who have received their full immunization series need not be immunized further.

Children who have received the primary series and a booster dose and are undergoing scheduled splenectomy (eg, for Hodgkin disease, spherocytosis) may benefit from an additional dose of any licensed conjugate vaccine given 7-10 days before the procedure.

Unimmunized children older than 59 months with an underlying disease may be immunized with 2 doses of vaccine 2 months apart.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!